Pemetrexed safety and pharmacokinetics in patients with third-space fluid

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Standard

Pemetrexed safety and pharmacokinetics in patients with third-space fluid. / Dickgreber, Nicolas J; Sørensen, Jens Benn; Paz-Ares, Luis G; Schytte, Tine Kjestrup; Latz, Jane E; Schneck, Karen B; Zheng, Yuan; Sanchez-Torres, José Miguel.

I: Clinical Cancer Research, Bind 16, Nr. 10, 15.05.2010, s. 2872-80.

Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt

Harvard

Dickgreber, NJ, Sørensen, JB, Paz-Ares, LG, Schytte, TK, Latz, JE, Schneck, KB, Zheng, Y & Sanchez-Torres, JM 2010, 'Pemetrexed safety and pharmacokinetics in patients with third-space fluid', Clinical Cancer Research, bind 16, nr. 10, s. 2872-80. https://doi.org/10.1158/1078-0432.CCR-09-3324

APA

Dickgreber, N. J., Sørensen, J. B., Paz-Ares, L. G., Schytte, T. K., Latz, J. E., Schneck, K. B., Zheng, Y., & Sanchez-Torres, J. M. (2010). Pemetrexed safety and pharmacokinetics in patients with third-space fluid. Clinical Cancer Research, 16(10), 2872-80. https://doi.org/10.1158/1078-0432.CCR-09-3324

Vancouver

Dickgreber NJ, Sørensen JB, Paz-Ares LG, Schytte TK, Latz JE, Schneck KB o.a. Pemetrexed safety and pharmacokinetics in patients with third-space fluid. Clinical Cancer Research. 2010 maj 15;16(10):2872-80. https://doi.org/10.1158/1078-0432.CCR-09-3324

Author

Dickgreber, Nicolas J ; Sørensen, Jens Benn ; Paz-Ares, Luis G ; Schytte, Tine Kjestrup ; Latz, Jane E ; Schneck, Karen B ; Zheng, Yuan ; Sanchez-Torres, José Miguel. / Pemetrexed safety and pharmacokinetics in patients with third-space fluid. I: Clinical Cancer Research. 2010 ; Bind 16, Nr. 10. s. 2872-80.

Bibtex

@article{351b7a188a4a4e488b5661a3efeeb25e,
title = "Pemetrexed safety and pharmacokinetics in patients with third-space fluid",
abstract = "Pemetrexed is established as first-line treatment with cisplatin for malignant pleural mesothelioma and advanced nonsquamous non-small-cell lung cancer (NSCLC) and as single-agent second-line treatment for nonsquamous NSCLC. Because the structure and pharmacokinetics of pemetrexed are similar to those of methotrexate, and methotrexate is associated with severe toxicity in patients with third-space fluid (TSF), the safety of pemetrexed in patients with TSF was evaluated.",
author = "Dickgreber, {Nicolas J} and S{\o}rensen, {Jens Benn} and Paz-Ares, {Luis G} and Schytte, {Tine Kjestrup} and Latz, {Jane E} and Schneck, {Karen B} and Yuan Zheng and Sanchez-Torres, {Jos{\'e} Miguel}",
note = "Copyright (c) 2010 AACR.",
year = "2010",
month = may,
day = "15",
doi = "http://dx.doi.org/10.1158/1078-0432.CCR-09-3324",
language = "English",
volume = "16",
pages = "2872--80",
journal = "Clinical Cancer Research",
issn = "1078-0432",
publisher = "American Association for Cancer Research (A A C R)",
number = "10",

}

RIS

TY - JOUR

T1 - Pemetrexed safety and pharmacokinetics in patients with third-space fluid

AU - Dickgreber, Nicolas J

AU - Sørensen, Jens Benn

AU - Paz-Ares, Luis G

AU - Schytte, Tine Kjestrup

AU - Latz, Jane E

AU - Schneck, Karen B

AU - Zheng, Yuan

AU - Sanchez-Torres, José Miguel

N1 - Copyright (c) 2010 AACR.

PY - 2010/5/15

Y1 - 2010/5/15

N2 - Pemetrexed is established as first-line treatment with cisplatin for malignant pleural mesothelioma and advanced nonsquamous non-small-cell lung cancer (NSCLC) and as single-agent second-line treatment for nonsquamous NSCLC. Because the structure and pharmacokinetics of pemetrexed are similar to those of methotrexate, and methotrexate is associated with severe toxicity in patients with third-space fluid (TSF), the safety of pemetrexed in patients with TSF was evaluated.

AB - Pemetrexed is established as first-line treatment with cisplatin for malignant pleural mesothelioma and advanced nonsquamous non-small-cell lung cancer (NSCLC) and as single-agent second-line treatment for nonsquamous NSCLC. Because the structure and pharmacokinetics of pemetrexed are similar to those of methotrexate, and methotrexate is associated with severe toxicity in patients with third-space fluid (TSF), the safety of pemetrexed in patients with TSF was evaluated.

U2 - http://dx.doi.org/10.1158/1078-0432.CCR-09-3324

DO - http://dx.doi.org/10.1158/1078-0432.CCR-09-3324

M3 - Journal article

VL - 16

SP - 2872

EP - 2880

JO - Clinical Cancer Research

JF - Clinical Cancer Research

SN - 1078-0432

IS - 10

ER -

ID: 34097115